Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. director Michael J. Embler received additional common stock units as compensation linked to dividends. On the grant date, he acquired 66.742 units of common stock at a closing price of $85.51 per share through the company’s Non-Employee Directors' Equity Award Deferral Program.
The units were credited as dividend equivalents on the dividend paid April 16, 2026 and are payable solely in common stock under his deferral election and the Program’s terms. After this award, Embler directly holds a total of 14,654.958 shares of Ventas common stock.
Barnes Melody C reported acquisition or exercise transactions in this Form 4 filing.
Ventas, Inc. director Melody C. Barnes received a grant of common stock units credited as dividend equivalents under the company’s Non-Employee Directors' Equity Award Deferral Program. The award totaled 66.742 shares based on the $85.51 closing price on April 16, 2026, increasing her direct holdings to 33,259.958 shares of common stock.
Ventas, Inc. director Maurice S. Smith received an award of 457.261 common stock units on April 1, 2026 under the company’s Non-Employee Directors' Cash Compensation Deferral Plan. The units were granted in lieu of director fees and are payable solely in common stock.
The grant was valued at $82.01 per share, representing the closing price of Ventas common stock on the grant date. Following this compensation-related acquisition, Smith directly holds a total of 28,549.613 shares of Ventas common stock.
Roy Sumit reported acquisition or exercise transactions in this Form 4 filing.
Ventas, Inc. director Sumit Roy received an award of 381.051 shares of common stock on April 1, 2026. The shares were granted as units under the company’s Non-Employee Directors' Cash Compensation Deferral Plan in lieu of cash director fees, based on a closing share price of $82.01. After this compensation-related grant, Roy directly holds a total of 22,240.765 shares of Ventas common stock.
LUSTIG MATTHEW J reported acquisition or exercise transactions in this Form 4 filing.
Ventas, Inc. director Matthew J. Lustig received an automatic grant of 396.293 shares of common stock-equivalent units on 2026-04-01. These units were awarded under the Ventas Non-Employee Directors' Cash Compensation Deferral Plan in lieu of cash director fees he elected to defer.
The units are payable solely in Ventas common stock and are subject to the terms of his deferral election and the plan. After this award, Lustig directly holds a total of 92,662.739 shares of Ventas common stock, reflecting his ongoing equity-based compensation as a board member.
Ventas, Inc. director Roxanne M. Martino received a grant of common stock units under the company’s Non-Employee Directors' Cash Compensation Deferral Plan. She acquired 624.924 common stock units in lieu of director fees at a reference price of $82.01 per share, increasing her direct holdings to 63,892.701 shares. The granted units are payable solely in common stock and are subject to the terms of her deferral election and the plan.
Ventas, Inc. presents its 2026 proxy, highlighting very strong 2025 performance and key governance votes. The company reports total shareholder return above 35% for 2025 and about 19% annualized since 2000, significantly outperforming major REIT and equity indices over multiple periods.
Financially, 2025 net income per share rose to $0.54, while Nareit FFO and Normalized FFO per share increased to $3.50 and $3.48, reflecting 11% and 9% growth. Total Company NOI grew 16% and Same-Store Cash NOI grew 8%, supported by demographic-driven demand in senior housing.
The proxy asks stockholders to elect 12 directors, approve executive compensation on an advisory basis and ratify KPMG as auditor for 2026. Ventas emphasizes a largely independent board, an experienced Lead Independent Director, robust succession planning, and compensation programs designed to align more than 80% of named executive officer target pay with performance and shareholder outcomes.
Ventas Inc: Schedule 13G/A amendment showing The Vanguard Group reports no beneficial ownership. The filing states 03/13/2026 and the amendment was signed 03/27/2026. It reports 0 shares beneficially owned and 0% of the class, with zero voting and dispositive power.
The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 causing certain Vanguard subsidiaries/divisions to report holdings separately. The statement clarifies Vanguard no longer is deemed to beneficially own securities held by those subsidiaries/divisions.
Ventas, Inc. submitted a Form 144 proposing the sale of common stock through UBS Financial Services Inc. on the NYSE, with the filing dated 03/02/2026. The filing lists ESOP-related lots dated 03/04/2016 (6,953 shares) and 03/10/2017 (10,295 shares).